← All trials
NCT05051735
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2021
- Primary completion
- Sep 30, 2023
- Completion date
- Dec 31, 2024
- First posted
- Sep 21, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 204
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- Telemark Hospital TrustCollaborator
- Telemark Hospital TrustOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.